Inflammatory bowel disease​ (IBD): Further reading and references for consumers

There are many safe and effective treatments for inflammatory bowel disease (IBD). Use the latest evidence to help you make decisions about your treatments in partnership with your IBD team.

Reference

Summary

Gastroenterological Society of Australia (GESA)

Clinical update for general practitioners and physicians, inflammatory bowel disease (updated 2018)

Provides guidance about the diagnosis and management of IBD.

European Crohn’s and Colitis Organisation (ECCO)

ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment

International recommendations for the management of Crohn’s disease.

European Crohn’s and Colitis Organisation (ECCO)

Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management

International recommendations for the management of ulcerative colitis.

Marshall et al, 2010 

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

A study of the effectiveness of rectal aminosalicylates (5-ASAs) for ulcerative colitis.

Marteau et al, 2005 

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

A study exploring the role of oral and rectal treatment versus oral medicines alone for ulcerative colitis.

Lemaitre et al,  2017 

Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease

A study assessing the risk of lymphoma associated with thiopurines and anti-TNF medicines in IBD.

Nielsen et al,  2020 

Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A  systematic review and meta-analysis of randomized, controlled trials

A study of the effectiveness and safety of methotrexate in IBD.